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Background: Recurrence rates following radiotherapy for prostate cancer in the post-operative adjuvant or salvage
setting remain substantial. Previous work from our institution demonstrated that published prostate bed CTV guidelines
frequently do not cover the pre-operative MRI defined prostate. Inadequate target delineation may contribute to the
high recurrence rates, but increasing target volumes may increase dose to organs at risk.
Methods: We propose guidelines for delineating post-prostatectomy target volumes based upon an individual’s
co-registered pre-operative MRI. MRI-based CTVs and PTVs were compared to those created using the RTOG
guidelines in 30 patients. Contours were analysed in terms of absolute volume, intersection volume (Jaccard Index)
and the ability to meet the RADICALS and QUANTEC rectal and bladder constraints (tomotherapy IMRT plans with
PTV coverage of V98% ≥98%).
Results: CTV MRI was a mean of 18.6% larger than CTV RTOG: CTV MRI mean 138 cc (range 72.3 - 222.2 cc), CTV RTOG
mean 116.3 cc (range 62.1 - 176.6 cc), (p < 0.0001). The difference in mean PTV was only 4.6%: PTV MRI mean 386.9 cc
(range 254.4 – 551.2), PTV RTOG mean 370 cc (range 232.3 - 501.6) (p = 0.05). The mean Jaccard Index representing
intersection volume between CTVs was 0.72 and 0.84 for PTVs. Both criteria had a similar ability to meet rectal and
bladder constraints. Rectal DVH: 77% of CTV RTOG cases passed all RADICALS criteria and 37% all QUANTEC criteria;
versus 73% and 40% for CTV MRI (p = 1.0 for both). Bladder DVH; 47% of CTV RTOG cases passed all RADICALS criteria
and 67% all QUANTEC criteria, versus 57% and 60% for CTV MRI (p = 0.61for RADICALS, p = 0.79 for QUANTEC). CTV
MRI spares more of the lower anterior bladder wall than CTV RTOG but increases coverage of the superior lateral
bladder walls.
Conclusion: CTV contours based upon the patient’s co-registered pre-operative MRI in the post-prostatectomy
setting may improve coverage of the individual’s prostate bed without substantially increasing the PTV size or
dose to bladder/ rectum compared to RTOG CTV guidelines. Further evaluation of whether the use of pre-operative
MRI improves local control rates is warranted.
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15-25% of all patients who undergo radical prostatec-
tomy relapse and, amongst those with high risk features
(positive margins, T3 disease), the rate of biochemical
recurrence (BCR) within 5 years is 45-75% [1-3]. Rando-
mised studies consistently report improved rates of local
control and biochemical progression free survival in
high risk prostate cancer patients following adjuvant
radiotherapy [4-6], with one study reporting improved
metastasis-free and overall survival [5]. Whether early
salvage radiotherapy at the first indication of BCR yields
outcomes equivalent to adjuvant treatment remains the
subject of further randomised studies.
However, despite adjuvant or salvage post-operative
radiotherapy, a large proportion of patients with high
risk disease recur. Mature data from patients who re-
ceived adjuvant radiotherapy within the above studies
report BCR rates of 40-50% at 10 years. SWOG 8794 in-
dicated that the pattern of treatment failure in high-risk
patients is predominantly local even with adjuvant radio-
therapy: 20% of the surgery only arm experienced local
relapse versus 7% of patients undergoing adjuvant radio-
therapy (12% versus 4% developed distant relapse) [7].
EORTC 22911 reported similar findings with long-term
local relapse identified in 7% of patients in the adjuvant
radiotherapy arm (a further 7.2% experienced metastatic
disease) [4]. Local failure post-radiotherapy results from
either inherent tumour radio-resistance/suboptimal dose
or inadequate target delineation. Whilst it can be argued
that the radiotherapy delivered in these studies was sub-
optimal by modern standards, the increasing use of
IMRT in an attempt to spare organs at risk could para-
doxically increase the local recurrence risk if the target
is not appropriately contoured.
It is essential that the post-operative clinical target vol-
ume (CTV) includes the entire prostate bed and planes of
surgical dissection as these are the areas at greatest risk
of possessing microscopic disease [8-10]. Four published
consensus guidelines have variously defined the post-
operative CTV in prostate cancer (European Organization
for Research and Treatment of Cancer [EORTC], Faculty
of Radiation Oncology Genito-Urinary Group [FROGG],
Princess Margaret Hospital [PMH], and Radiation Therapy
Oncology Group [RTOG]) [11-14]. The CTV borders in
each of these guidelines are based upon anatomical land-
marks and important differences exist between guidelines.
Only the EORTC guidelines specifically take account of the
pathology report, recommending a 5 mm expansion in the
direction of a positive margin, although the CTV FROGG
makes reference to surgical clips. Previous work from our
institution showed that none of the four guidelines ad-
equately covered the prostate bed and/or gross tumour
based on preoperative MRI in a non-select group of 20 pa-
tients [15]. On average, 38% of the prostate volume and41% of gross tumour volume on pre-operative MRI were
not included in the CTV. The CTV RTOG and CTV
PMH provided the best coverage with the CTV-EORTC
being the least adequate. This suggests that improved tar-
get delineation could potentially improve outcomes.
We therefore propose an alternative CTV for post-
operative radiotherapy to the prostate bed that incorpo-
rates information from each patient’s pre-operative MRI
(CTV MRI) and have evaluated this in comparison to
the RTOG guidelines in terms of target volume and
doses to the rectum and bladder.
Methods
Patient cohort
The clinical study was approved by the institution’s
Research Ethics Board. A list of prostate cancer patients
who underwent radical prostatectomy (RP) and adjuvant
or salvage radiotherapy from May 2007 to January 2011
at our institution was compiled and the first 30 patients
(chosen alphabetically) with pre-operative staging pelvic
MRI comprised the study group. The decision for pre-
operative MRI staging had been at the discretion of the
treating Urologist. Patients were excluded if they had an
endo-rectal coil placed during the preoperative MRI as
the probe can result in compression and displacement of
the prostate.
Planning CT and MRI parameters
All patients had undergone radiotherapy treatment plan-
ning CT scans in a supine position with a rubber leg
cushion immobilization device and full bladder/empty
rectum (achieved via a fleet enema prior to CT Simulation).
The planning CT scan extended from 5 cm above the
L5-S1 vertebral body to 5 cm below the ischial tuberos-
ity using 3 mm axial slices. Planning CT scans for the
30 patients were imported into a CMS Focal planning
station for contouring.
Pre-operative MRIs were performed on either a Siemens
Trio Tim (3 T), Symphony Tim (1.5 T) or Symphony
(1.5 T) scanner. 3-5 mm T2-weighted turbo spin echo and
4-5 mm T1-weighted fat saturation fast low angle shot
pre- and post-gadolinium (at 1 and 2 min) scans were
available in the axial, coronal and sagittal planes. Axial T1
post-gadolinium and T2 images were co-registered to the
planning CT scan using the “auto fusion” function and ad-
justed manually as required to provide optimal fusion in all
three planes using pelvic bone landmarks.
Contouring
Two CTVs were contoured for each patient: the first CTV
followed the RTOG Consensus guideline (CTV RTOG)
and the second was based on the pre-operative MRI (CTV
MRI). Two radiation oncologists (JC and SM) jointly con-
toured all of the targets and the MRI contours were
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accurate delineation. Furthermore, for quality assurance
purposes, the CTV RTOG guideline was reviewed in
detail at the initiation of this study by the 7 Radiation
Oncologists specialising in genitourinary (GU) malig-
nancy at our institution. For each patient the following
landmarks were contoured on the treatment planning
CT Scan: rectum, bladder, vesicourethral anastomosis,
penile bulb, and bladder neck. The CTV RTOG was con-
toured for each patient according to the protocol sum-
marised in Table 1 using the planning CT scan only.
Where the RTOG guidelines specified a range of possible
anatomical borders, the largest was chosen in each case
to provide the most generous CTV.
CTV MRI
The prostate, seminal vesicles and any gross visible tumour
were contoured using the co-registered MRI. Gross
tumour was identified as a hypointense lesion on T2 MRI
and/or enhancing tumour on T1 post -gadolinium MRI.
The CTV MRI was created as follows:
1. The prostate and any gross visible tumour extending
outwith the prostate was expanded by 5 mm to
account for potential extra-prostatic extension
2. This volume was tailored to respect anatomic
barriers including the fascia of the pelvic muscles,
the periosteum of the pubic symphysis and
Denovillier’s fascia along the anterior rectum.
3. In cases where there was a geographic shift of the
rectum between the pre-operative MRI and the
post-operative CT simulation, CTV MRI was tailored
to exclude the anterior rectal wall. In these cases CTV
MRI was extended laterally to include the peri-rectal
fat space that could harbour microscopic disease
(including the pre-operative MRI defined prostate
plus 5 mm).
4. To include the planes of surgical dissection the CTV
MRI was extended to include all surgical clips andTable 1 RTOG Consensus CTV Guidelines
Location Anatomical border
Below superior edge of pubic symphysis
Anterior Posterior edge of pubic bone
Posterior Anterior rectal wall (may need to be concave around lateral a
Lateral Levator ani muscles, obturator internus
Inferior 8-12 mm below vesicourethral anastomosis (may include mo
if concern for apical margin. Can extend to slice above penile
bulb if vesicourethral anastomosis not well visualized)
Superior N/Ato the medial fascia of the levator ani/obturator
internus muscle.
5. CTV MRI was trimmed superiorly where there was a
prominent median lobe (benign prostatic hypertrophy)
projecting into the bladder. In these cases the inferior
bladder wall lies adjacent to the prostate and
there is no adjacent peri-prostatic fat. During
radical prostatectomy the bladder neck is pulled down
inferiorly and attached to the urethra. In cases where
there is pelvic fat adjacent to the base of the prostate
and or gross tumour, CTV MRI was not tailored. For
these cases, the fat space remains attached to the
pelvic side wall and pubic symphysis and is at risk for
harbouring microscopic residual disease.
6. Seminal vesicle coverage was done in accordance
with the CTV RTOG guideline.
PTV
PTV RTOG and PTV MRI were created using a 1 cm
isotropic expansion of the respective CTVs.
Treatment planning
Two tomotherapy IMRT plans were created for all 30
cases (PTV RTOG and PTV MRI). A dose of 6600 cGy
in 33 fractions was used to cover the PTV, as per the
RADICALS protocol [16]. Inverse planning was per-
formed using Tomotherapy Planning Software (TPS)
Version 4.0. Plans were optimized to minimize both rec-
tal and bladder doses and to provide PTV coverage of
V98% ≥100%. A beam width of 2.5 cm and a pitch of
0.287 were used for each plan.
Analysis
The mean and range volumes for the CTVs and PTVs
were calculated and the statistical significance of the
difference in absolute volumes assessed using a paired
t-test. The Jaccard Index was calculated for CTVs and
PTVs in each case to provide a measure of the similar-
ity between volumes. This is derived by dividing theAbove superior edge of pubic symphysis
Posterior 1-2 cm of bladder wall
spects) Mesorectal fascia
Sacrorectogenitopubic fascia (if concern about extraprostatic
disease at base may extend to obturator internus)
re N/A
Level of cut end of vas deferens or 3-4 cm above top of
symphysis (Vas may retract postoperatively; include seminal
vesicle remnants if pathologically involved)
Figure 1 Box and whiskers plot for absolute and overlap
CTV/ PTVs. The whiskers are located at the maximum and minimum
values; the box shows the 25-75th centiles with the median marked.
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PTV) by the union volume of both CTVs (or PTVs). A
Jaccard Index of 1 equates to 100% overlap and 0 means
no overlap:
Jaccard Index ¼ CTV RTOG ∩ CTV MRI
CTV RTOG ∪ CTV MRI
Dose volume histograms (DVHs) were evaluated for
ability to meet the desired target coverage and OAR
(rectum and bladder) dose constraints set forth by RAD-
ICALS [16] and QUANTEC [17] guidelines (Table 2)
which were recorded as pass/fail. The statistical signifi-
cance of differences in the ability to meet dose con-




The CTV MRI was a mean of 18.6% larger than CTV
RTOG (larger in 26 cases): CTV MRI mean 138 cc
(range 72.3 - 222.2 cc), CTV RTOG mean 116.3 cc
(range 62.1 - 176.6 cc), (p < 0.0001). The addition of the
isotropic PTV margins reduced this difference to only
4.6% (PTV MRI larger in 21 cases); PTV MRI mean
386.9 cc (range 254.4 – 551.2), PTV RTOG mean 370 cc
(range 232.3 - 501.6), (p = 0.05). The mean Jaccard Index
was 0.72 for CTV (standard deviation 0.09) and 0.84 for
PTV (SD 0.06). Graphical depiction of absolute and
overlap volumes is shown in Figure 1. Figure 2 shows a
typical example of differences in the volumes for one
case.
The desired PTV coverage of V98% of 98% was met in
all cases for both PTV RTOG and PTV MRI.
Organs at risk
Table 3 details the adherence to each OAR constraint
for plans created to cover the PTVs created using CTV
RTOG and CTV MRI. Both failed to meet the OAR dose
constraints proposed by RADICALS and QUANTEC inTable 2 Relevant DVH Constraints for Rectum and Bladder
in RADICALS and QUANTEC
Constraint Rectum Bladder
(Gy) RDICALS QUANTEC RADICALS QUANTEC
30 <80% - - -
40 <70% - - -
50 <60% <50% <80% -
60 <50% <35% <50% -
65 - <25% - <50%
66 <30% - - -
70 - <20% - <35%a considerable number of cases and there were no sig-
nificant differences between either contouring criteria.
For the rectal DVH: 77% of CTV RTOG cases passed
all the RADICALS criteria and 37% all the QUANTEC
criteria; versus 73% and 40% for CTV MRI (p = 1.0 for
both). For the bladder DVH; 47% of CTV RTOG cases
passed all the RADICALS criteria and 67% all the
QUANTEC criteria versus 57% and 60% for CTV MRI
(p = 0.61for RADICALS and p = 0.79 for QUANTEC).
Plans created using CTV MRI generally spare more of
the inferior anterior bladder wall compared to CTV
RTOG; however, CTV MRI results in greater treatment of
the lateral bladder wall (Figure 2). Both CTVs were simi-
larly better able to meet the V50 proposed by RADICALS
compared to V60 (p = 1.0).
Discussion
When post-operative radiotherapy is undertaken the de-
lineation of an appropriate CTV is integral to treatment
success regardless of whether this is delivered in the ad-
juvant or salvage setting. In other cancer sites, radiation
oncologists generally aim to cover the entire surgical
bed and use information from surgical and pathology re-
ports as well as pre and post-operative imaging to define
the CTV. However, the four published post-operative
prostate radiation CTV guidelines are largely based on
anatomic boundaries rather than the individual’s surgical
bed and significant volumetric differences exist between
guidelines [15].
The rationale for post-operative radiotherapy in high risk
patients is that the majority of initial post-prostatectomy
relapses appear to be local [7]. However, randomised stud-
ies of post-prostatectomy radiotherapy still report high re-
lapse rates following radiotherapy. Ten year follow-up in
SWOG 8794 reported BCR in 42% of post-prostatectomy
patients with pre-treatment PSAs ≤0.2 who had undergone
Figure 2 Typical case depicting the differences in shape and coverage between CTV RTOG and CTV MRI. Key - Purple: pre-op prostate,
Blue: pre-op visible tumour, Red: CTV RTOG, Green: CTV MRI, Yellow: bladder. (a) pre-operative T2 MRI (b) planning CT scan (post-operative); the
bladder neck has been pulled down. (c) CTV RTOG does not completely cover the region of the pre-operative prostate/ tumour. Although the
bladder will now largely fill the location of the original prostate, the lateral soft tissue lateral remains at risk of microscopic disease. (d) CTV MRI
extends 5 mm around the original prostate to cover the soft tissue that was adjacent to the prostate (e) Inferiorly the CTV RTOG treats more of
the anterior bladder wall than CTV MRI where coverage may not be required in view of the original prostate location. (f) Superiorly the CTV MRI
increases dose to the lateral bladder walls because it covers the soft tissue beside the bladder that remains at risk of microscopic disease in view
of the original prostate/tumour location. CTV RTOG misses these areas.
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confirmed metastatic disease) [5]. Similarly, after the
same median follow-up in EORTC 22911 39.4% of pa-
tients had BCR, clinical progression or had died and PFS
rates in the ARO 96-02 study were 56% (BCR, local or
metastatic disease) [4,6]. This suggests inadequacies in
radiotherapy delivery or dose. It should be emphasised
that of these adjuvant radiotherapy studies, only ARO
96-02 used CT-based contouring/ planning. Therefore,
adherence to any of the four current CT-based CTVconsensus guidelines could reasonably be expected to
result in better target coverage. On the other hand, our
previous work suggested that the consensus guidelines
did not adequately cover the prostate bed and the move
towards IMRT as the standard method of delivering post-
prostatectomy radiotherapy therefore has the potential to
result in more treatment failures [15].
Malignant cells located in the extra-prostatic fat space
(at sites of extra-prostatic extension and positive mar-
gins) are unlikely to be pulled down with the bladder
Table 3 Percentage of cases where the plan created for PTV RTOG and PTV MRI passed the criteria
% Passing Criteria (n)
Rectum Bladder
RADICALS QUANTEC RADICALS QUANTEC
Constraint RTOG MRI RTOG MRI RTOG MRI RTOG MRI
V30 83 (25/30) 77 (23/30) - - - - - -
V40 93 (28/30) 97 (29/30) - - - - - -
V50 93 (28/30) 83 (25/30) 40 (12/30) 60 (18/30) 73 (22/30) 70 (21/30) - -
V60 93 (28/30) 90 (27/30) 37 (11/30) 40 (12/30) 47 (14/30) 57 (17/30) - -
V65 - - - - - - 67 (20/30) 60 (18/30)
V66 77 (23/30) 73 (22/30) - - - - - -
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CTV delineation may not adequately cover this region
as it is dependent on individual anatomy. We have there-
fore proposed an individualised post-operative CTV based
on the patient’s pre-operative MRI. The RTOG guidelines
were chosen as the comparator as they best covered the
prostate bed in our previous study. The paper detailing the
RTOG guidelines acknowledges that pre-operative imaging
can help establish the superior extent of the CTV, but
makes no specific recommendations regarding this [14].
Extra-prostatic extension typically extends within 5 mm
of the prostate [18,19], hence our 5 mm CTV expansion
beyond the MRI defined prostate. Coverage of seminal
vesicles was done in accordance to the RTOG guideline.
As per the ICRU definition of CTV, we restricted our
CTV definition to anatomic boundaries. Furthermore,
coverage of the prostate base was modified in cases where
there was a prominent median lobe suggestive of benign
prostatic hypertrophy. We included the fat space lateral to
the prostate up to the levator ani as these tissues are not
pulled down with the bladder during prostatectomy and
therefore are at risk for harbouring microscopic disease.
Our previous research indicated that the predominant site
of geographic miss using the four consensus guidelines
was the base region of the prostate [15]. Wang et al., re-
cently evaluated regions of local recurrence after RP in re-
lation to whether these would have been covered using
the RTOG guidelines [20]. They reported that RTOG
CTV contours did not appear adequate posterolaterally
near the rectum/mesorectal fascia and inferiorly at the
posterior urogenital diaphragm. Use of the CTV MRI
should improve coverage of such regions.
CTV MRI was larger in terms of absolute volume than
CTV RTOG, but this difference was <5% when isometric
PTV margins were applied. However, there was a more
significant difference between contours in volumetric
shape (a mean of 16% of PTV was outside of the overlap
volume). CTV RTOG extends to the top of the pubic
symphysis anteriorly, while CTV MRI is tailored in this
region to follow the preoperative prostate and sites ofpotential extra-prostate spread (prostate plus 5 mm). As
a result of this shape difference CTV MRI is able to
spare the inferior bladder wall anteriorly as compared to
CTV RTOG. Adequate coverage of the pre-operative
prostate base within CTV MRI increased dose to the su-
perior portion of the lateral bladder walls compared to
CTV RTOG, but IMRT plans created for both PTVs
met the dose constraints proposed by RADICALS and
QUANTEC in a similar percentage of cases. This is re-
assuring in that it indicates that the use of CTV MRI
should not result in greater normal tissue toxicity than
CTV RTOG. However, both CTVs failed to meet all the
rectal and bladder constraints in a large percentage of
cases. It should be noted of course that a large percent-
age of the bladder in the treatment field is not bladder
wall and treatment of the urine-filled volume is unlikely
to cause toxicity. There is currently a paucity of clinical
data validating current DVH guides in the post-operative
setting. Therefore, as the CTV MRI clearly defines re-
gions at high risk of relapse for the individual, whether it
is appropriate to compromise CTV coverage to meet all
of the OAR dose constraints needs careful consideration.
Information from ongoing randomised clinical trials will
help researchers to define optimal DVHs for OARs in
this patient population.
There are various limitations in this study in relation
to the use of MRI. MRI and planning CT were automat-
ically co-registered in relation to bony contours and
manually adjusted as required, as described in reports of
CT/MRI coregistration in the primary radiotherapy set-
ting [21,22]. There are inherent limitations to such co-
registrations in the pelvis due to variable bowel and
bladder filling. Such uncertainties are likely increased in
the post-prostatectomy setting as periprostatic tissue
may move relative to the bones and we noted changes in
rectal wall position in many patients. However, the CTV
MRI was tailored accordingly and daily image guidance
should be used during radiotherapy to offset interfrac-
tion organ position changes as much as possible. Sec-
ondly, there remains debate regarding the optimal MRI
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cant interobserver variability in image interpretation/
contouring. As such we chose to co-register simple and
widely available T1 post-contrast and T2 series. These
are familiar to most prostate radiation oncologists and
our MRI contours were reviewed by an expert MRI pelvis
radiologist. As we were largely interested in the superfi-
cial anatomy of the prostate, it is unlikely that more ad-
vanced MRI sequences or 3 Tesla imaging would have
significantly improved prostate bed coverage and less fa-
miliar sequences could have added to interpretation un-
certainties. Furthermore, interobserver variability is not
unique to MRI - the delineation of the post-prostatectomy
target volume using the EORTC consensus guidelines
(without MRI) showed only moderate observer agreement
[23]. It would be interesting to evaluate contouring
consistency using CTV MRI against any of the consensus
guidelines in a future study. Endorectal coils were not
used in our patients as they can deform the prostate and
are thus avoided when co-registration for radiotherapy is
anticipated. It is important that centres consider this when
formulating imaging protocols as several studies indicate
that endorectal coils improve diagnostic image quality and
their use is recommended in the ESUR prostate cancer
staging protocol [24].
Finally, a fundamental issue that could hamper the
widespread adoption of CTV MRI is the considerable
disparity that remains in many regions regarding routine
MRI use, despite the fact that MRI is increasingly rec-
ommended in prostate cancer guidelines. MRI is more
accurate than DRE at defining prostate T stage, better
correlates with post-radiation outcomes and provides im-
portant nodal evaluation in higher risk patients [24-27].
Furthermore, MRI-based radiotherapy target volumes
are smaller than CT-based targets with less inter/intra-
observer variability [21,28] and MRI may also improve
surgical planning, particularly in terms of whether to spare
or resect the neurovascular bundles [29,30]. As such, the
2012 European Society of Urogenital Radiology (ESUR)
guidelines conclude that multiparametric MRI is an inte-
gral part of prostate cancer diagnosis and management for
all risk categories of patients, including those considering
active surveillance [24]. Additionally, the UK National
Institute of Health and Care Excellence (NICE) guidelines,
which consider clinical benefit and cost effectiveness, rec-
ommend a multiparametric MRI scan in men with histo-
logically proven prostate cancer when knowledge of the
T or N stage could affect management [31] (effectively
all candidates for radical treatment/active surveillance).
However, the 2013 American College of Radiology ACR
Appropriateness Criteria® support routine MRI only in
patients with intermediate to high risk prostate cancer
and for some low-risk cases prior to active surveillance
[32]. Regardless, this should have limited impact on thepotential for CTV MRI use as very few patients deemed
to be low risk by other parameters are likely to require
post-operative radiotherapy.
Conclusion
This study proposes a post-prostatectomy CTV tailored
to the individual by using the co-registered pre-operative
MRI, which appears to better cover each individual’s
prostate bed without substantially increasing the PTV
size. Volumetric shape differences between CTV RTOG
and CTV MRI result in different locations of the bladder
wall receiving high dose radiation. However, this did not
impact upon the ability of CTV MRI to meet currently
used OAR dose constraints. This suggests that the use of
CTV MRI would be a safe approach to post-prostatectomy
radiotherapy targeting. Whether the use of CTV MRI
would translate into improved patient outcomes remains a
hypothesis that would have to be tested within a prospect-
ive clinical study.
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